🧬New Biotech Venture Fund launches Amid NIH Funding uncertainty
The biotech industry is facing uncertainty as the Trump administration pushes for limits on NIH funding for research institutions. While a federal judge has temporarily blocked the move, early-stage biotech startups relying on SBIR grants could still face funding delays or cuts.
🌼Enter Altitude Lab Pre-seed Venture Fund – a new initiative by Recursion CEO Chris Gibson and biotech entrepreneur David Bearss. This fund will invest $100K–$250K in 10–15 biotech startups, offering early support in a critical time.
🔬Why It Matters:
✅ NIH grants have been a key funding source for biotech startups ✅ Recursion itself got a $1.46M SBIR grant in 2014, fueling its AI-driven drug discovery platform ✅ The fund provides startups with 12 months of office & lab space at Salt Lake City’s Altitude Lab
đź’ˇGibson's Vision: Build a mini-Cambridge in Salt Lake City & help promising biotechs survive funding gaps.
With biotech innovation at stake, this fund could be a lifeline for groundbreaking startups.
What do you think? Will private capital step in as government funding wavers?
🧬New Biotech Venture Fund launches Amid NIH Funding uncertainty
The biotech industry is facing uncertainty as the Trump administration pushes for limits on NIH funding for research institutions. While a federal judge has temporarily blocked the move, early-stage biotech startups relying on SBIR grants could still face funding delays or cuts.
🌼Enter Altitude Lab Pre-seed Venture Fund – a new initiative by Recursion CEO Chris Gibson and biotech entrepreneur David Bearss. This fund will invest $100K–$250K in 10–15 biotech startups, offering early support in a critical time.
🔬Why It Matters:
✅ NIH grants have been a key funding source for biotech startups ✅ Recursion itself got a $1.46M SBIR grant in 2014, fueling its AI-driven drug discovery platform ✅ The fund provides startups with 12 months of office & lab space at Salt Lake City’s Altitude Lab
đź’ˇGibson's Vision: Build a mini-Cambridge in Salt Lake City & help promising biotechs survive funding gaps.
With biotech innovation at stake, this fund could be a lifeline for groundbreaking startups.
What do you think? Will private capital step in as government funding wavers?
Telegram is an aspiring new messaging app that’s taking the world by storm. The app is free, fast, and claims to be one of the safest messengers around. It allows people to connect easily, without any boundaries.You can use channels on Telegram, which are similar to Facebook pages. If you’re wondering how to find channels on Telegram, you’re in the right place. Keep reading and you’ll find out how. Also, you’ll learn more about channels, creating channels yourself, and the difference between private and public Telegram channels.
However, analysts are positive on the stock now. “We have seen a huge downside movement in the stock due to the central electricity regulatory commission’s (CERC) order that seems to be negative from 2014-15 onwards but we cannot take a linear negative view on the stock and further downside movement on the stock is unlikely. Currently stock is underpriced. Investors can bet on it for a longer horizon," said Vivek Gupta, director research at CapitalVia Global Research.
